Killer-cell Immunoglobulin-like Receptor (KIR) gene profiles modify HIV disease course, not HIV acquisition in South African women

Naranbhai, V.; de Assis Rosa, D.; Werner, L.; Moodley, R.; Hong, H.; Kharsany, A.; Mlisana, K.; Sibeko, S.; Garrett, N.; Chopera, D.; Carr, W. H.; Abdool Karim, Q.; Hill, A. V. S.; Abdool Karim, S. S.; Altfeld, M.; Gray, C. M.; Ndung’u, T.

doi:10.1186/s12879-016-1361-1

Table 1 Results of logistic regression model of KIR/HLA and HIV acquisition

From: Killer-cell Immunoglobulin-like Receptor (KIR) gene profiles modify HIV disease course, not HIV acquisition in South African women

	HIV- (n = 155)			HIV+ (n = 154)			p^a	OR^a	95 % CI^a
	-	+	+ %	-	+	+ %
KIR loci
KIR2DL1	4	151	97.4 %	0	154	100.0 %	0.98	-	-
KIR2DL2	45	110	71.0 %	46	107	69.9 %	0.89	1.04	0.63–1.71
KIR2DL2/KIR2DL2		39	25.5 %		35	22.9 %
KIR2DL2/KIR2DL3		70	45.8 %		72	47.1 %	0.63	1.15	0.43–2.05
KIR2DL3/KIR2DL3		44	28.8 %		46	30.1 %	0.83	1.07	0.32–2.00
KIR2DL3	40	114	74.0 %	35	118	77.1 %	0.61	1.15	0.68–1.94
KIR2DL4	3	152	98.1 %	0	154	100.0 %	0.98	-	-
KIR2DL5	44	111	71.6 %	56	98	63.6 %	0.18	0.72	0.44–1.16
KIR3DL1	0	155	100.0 %	0	154	100.0 %	-	-	-
KIR3DL1/KIR3DL1		145	94.8 %		141	92.2 %
KIR3DL1/KIR3DS1		8	5.2 %		12	7.8 %	0.27	1.69	0.62-4.04
KIR3DS1/KIR3DS1		0	0.0 %		0	0.0 %	-	-	-
KIR3DS1	145	8	5.2 %	141	12	7.8 %	0.27	1.69	0.67–4.45
KIR3DL2	0	155	100.0 %	0	154	100.0 %	-	-	-
KIR3DL3	2	153	98.7 %	0	154	100.0 %	0.98	-	-
KIR2DS1	135	18	11.8 %	130	24	15.6 %	0.23	1.51	0.78–2.96
KIR2DS2	63	92	59.4 %	60	94	61.0 %	0.56	1.15	0.72–1.83
KIR2DS3	104	51	32.9 %	111	43	27.9 %	0.43	0.82	0.50–1.34
KIR2DS3/KIR2DS3		29	25.9 %		24	24.2 %
KIR2DS3/KIR2DS5		22	19.6 %		19	19.2 %	0.77	1.13	0.49–2.60
KIR2DS5/KIR2DS5		61	54.5 %		56	56.6 %	0.77	1.11	0.57–2.14
KIR2DS5	72	83	53.5 %	79	75	48.7 %	0.47	0.85	0.54–1.33
KIR2DS4^b	2	153	98.7 %	1	153	99.4 %	0.63	1.80	0.17–39.03
197/.		23	20.2 %		11	19.0 %
197/219		31	27.2 %		25	43.1 %	0.25	1.57	0.70–4.21
./219		60	52.6 %		22	37.9 %	0.55	1.56	0.32–1.87
KIR Haplotype
Bx	33	121	78.6 %	40	113	73.9 %	0.45	0.81	0.48–1.39
AA		33	21.4 %		40	26.1 %
AB		77	50.0 %		78	51.0 %	0.65	0.88	0.50–1.55
BB		44	28.6 %		35	22.9 %	0.27	0.70	0.36–1.33
HLA Groups
Protective B alleles	122	33	21.3 %	128	26	16.9 %	0.33	0.75	0.42–1.33
Harmful B alleles	108	47	30.3 %	104	50	32.5 %	0.80	1.07	0.66–1.73
Bw4	109	46	29.7 %	103	51	33.1 %	0.50	1.18	0.73–1.92
Bw6	75	80	51.6 %	77	77	50.0 %	0.70	0.92	0.58–1.44
C1/C1		21	13.5 %		18	11.7 %
C1/C2		68	43.9 %		73	47.4 %	0.76	1.35	0.65–2.81
C2/C2		66	42.6 %		63	40.9 %	0.70	1.18	0.56–2.52
KIR/HLA Ligand Pair
KIR2DL1_C2	33	122	78.7 %	25	129	83.8 %	0.22	1.44	0.81–2.59
KIR2DS1_C2	140	15	9.7 %	132	22	14.3 %	0.15	1.68	0.84–3.46
KIR2DL2_C1	90	65	41.9 %	92	62	40.3 %	0.77	0.93	0.59–1.47
KIR2DL3_C1	94	61	39.4 %	85	69	44.8 %	0.43	1.20	0.76–1.90
KIR3DL1_Bw4	109	46	29.7 %	103	51	33.1 %	0.50	1.18	0.73–1.92
KIR3DS1_Bw4	150	5	3.2 %	148	6	3.9 %	0.68	1.29	0.38–4.59
KIR2DS4_Cw04	128	27	17.4 %	128	26	16.9 %	0.86	1.04	0.57–1.91
KIR3DL2_A3A11	134	21	13.5 %	133	21	13.6 %	0.98	1.01	0.52–1.95

Previous Presentations: A part of these data was presented at the International Immunogenetics and HLA Workshop 2012. Liverpool, UK, 28 May-3 June 2012
^a(adjusted for tenofovir gel use)
^bFor a subset (172/309, 56 %) KIR2DS4 alleles were genotyped where 197 denotes the common deletion variant of KIR2DS4 that has a 22 bp deletion in exon 5

Back to article page

ISSN: 1471-2334

Contact us

Submission enquiries: bmcinfectiousdiseases@biomedcentral.com
General enquiries: ORSupport@springernature.com

BMC Infectious Diseases

Contact us